 In this study, it was found that erythropoietin, EPO, can reduce kidney damage caused by hemorrhagic shock, HS. This is due to its ability to decrease levels of pro-inflammatory cytokines such as TNF-alpha and IL-6, while increasing levels of anti-inflammatory cytokine IL-10. These findings suggest that EPO could potentially be used to treat patients with HS. This article was authored by Meena Ranjbaran, Mary Katkadi and Bijat Siafai.